Crinetics ( CRNX ) Q2 Revenue Jumps 150%
Crinetics Pharmaceuticals ( NASDAQ:CRNX ) , a biotechnology company focused on developing oral therapies for rare endocrine diseases, reported its latest quarterly results on August 7, 2025, for the second quarter of fiscal 2025.
Crinetics Pharmaceuticals, Inc. ( CRNX ) Reports Q2 Loss, Lags Revenue Estimates
CRINETICS PHARM (CRNX) delivered earnings and revenue surprises of -8.85% and -79.78%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Crinetics Pharmaceuticals, Inc. ( CRNX ) Q2 Earnings Expected to Decline
CRINETICS PHARM (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Crinetics Reports Durable Symptom, Hormone Control With Oral Drug In Acromegaly - Crinetics Pharmaceuticals ( NASDAQ:CRNX )
IGF-1 levels remained stable at week 96 for PATHFNDR-1 patients switched to oral palsonify. Daily symptom flares dropped from over 30% on injectables to 6.2% with palsonify in PATHFNDR-1. Get daily-updated rankings across momentum, growth, value, trends, and quality to spot the strongest stocks ...
Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ ( Paltusotine ) in Acromegaly at ENDO 2025
Data show that PALSONIFY was well tolerated and IGF-1 levels remained stably controlled during long-term open label extensions of PATHFNDR-1 and PATHFNDR-2 studies ...
Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025
SAN DIEGO, July 11, 2025 ( GLOBE NEWSWIRE ) -- Crinetics Pharmaceuticals, Inc. ( Nasdaq: CRNX ) today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025 after the market closes. Company management will host a conference call at 4:30 p.m.
Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN DIEGO, July 10, 2025 ( GLOBE NEWSWIRE ) -- Crinetics Pharmaceuticals, Inc. ( Nasdaq: CRNX ) today announced that on July 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 102,350 shares of its common stock and ...
Ionis Pharmaceuticals ( IONS ) Moves 9.1% Higher: Will This Strength Last?
Ionis Pharmaceuticals (IONS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline - Crinetics Pharmaceuticals ( NASDAQ:CRNX )
Long-term efficacy and safety data on PALSONIFYTM ( paltusotine ) in acromegaly to be presented, including evidence of both biochemical and symptom control with a well-tolerated safety profile in patients switching treatments and those not previously pharmacologically treated
Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline
Long-term efficacy and safety data on PALSONIFYTM ( paltusotine ) in acromegaly to be presented, including evidence of both biochemical and symptom control with a well-tolerated safety profile in patients switching treatments and those not previously pharmacologically treated ...
Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025
SAN DIEGO, May 23, 2025 ( GLOBE NEWSWIRE ) -- Crinetics Pharmaceuticals, Inc. ( Nasdaq: CRNX ) , today announced that company management will participate in the Jefferies Global Healthcare Conference, taking place June 3-5, 2025 in New York, NY.
Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Crinetics Pharmaceuticals ( NASDAQ:CRNX )
SAN DIEGO, May 12, 2025 ( GLOBE NEWSWIRE ) -- Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc. ( CRNX ) Reports Q1 Loss, Tops Revenue Estimates
Crinetics Pharmaceuticals (CRNX) delivered earnings and revenue surprises of -5.05% and 261%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders - Keros Therapeutics ( NASDAQ:KROS )
Announces Intention to Withhold Votes for Directors Dr. Mary Ann Gray and Dr. Alpna Seth
Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025
SAN DIEGO, April 11, 2025 ( GLOBE NEWSWIRE ) -- Crinetics Pharmaceuticals, Inc. ( Nasdaq: CRNX ) today announced that it will report first quarter 2025 financial results on Thursday, May 8, 2025 after the market closes. Company management will host a conference call at 4:30 p.m.
Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN DIEGO, April 10, 2025 ( GLOBE NEWSWIRE ) -- Crinetics Pharmaceuticals, Inc. ( Nasdaq: CRNX ) today announced that on April 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 124,950 shares of its common stock ...
3 Destinations Mutual Funds to Buy for Consistent Returns
Consider investing in Destinations mutual funds such as DGEFX, DMSFX and DLDFX for a diversified investment approach.
JP Morgan Survey: 90% Of Endocrinologists Are Aware Of Crinetics' Atumelnant Data - Crinetics Pharmaceuticals ( NASDAQ:CRNX )
90% of surveyed endocrinologists were familiar with Atumelnant's Phase 2 data, with ~63% having a favorable view of its efficacy. JP Morgan sees Crinetics as a strong player in endocrine R&D, with cash runway through 2029 and a growing pipeline beyond paltusotine. Feel unsure about the market's ...
Crinetics Pharmaceuticals Analyst Sees Around 70% Upside For Stock, Cites More Investor Interest In Endocrinology - Crinetics Pharmaceuticals ( NASDAQ:CRNX )
Stifel initiateds coverage on Crinetics citing strong potential for Paltusotine and Atumelnant. Paltusotine, under FDA review for acromegaly, has a PDUFA target date of Sept. 25, 2025, with peak global sales projected at $2 billion. Pelosi's latest AI pick skyrocketed 169% in just one month.
This Clearway Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Avalo Therapeutics ( NASDAQ:AVTX ) , Assembly Biosciences ( NASDAQ:ASMB )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Deutsche Bank analyst Corinne Blanchard initiated coverage on Clearway Energy, Inc.
Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN DIEGO, March 10, 2025 ( GLOBE NEWSWIRE ) -- Crinetics Pharmaceuticals, Inc. ( Nasdaq: CRNX ) today announced that on March 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 95,675 shares of its common stock to ...
3 Driehaus Mutual Funds for Long-term Returns
Invest in Driehaus mutual funds like DVSMX, DMAGX and DRESX for a diversified portfolio.
Crinetics Pharmaceuticals Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN DIEGO, Feb. 10, 2025 ( GLOBE NEWSWIRE ) -- Crinetics Pharmaceuticals, Inc. ( Nasdaq: CRNX ) today announced that on February 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 105,100 shares of its common stock ...
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 - Crinetics Pharmaceuticals ( NASDAQ:CRNX )
SAN DIEGO, Feb. 06, 2025 ( GLOBE NEWSWIRE ) -- Crinetics Pharmaceuticals, Inc. CRNX today announced that it will report fourth quarter and full year 2024 financial results on Thursday, February 27, 2025 after the market closes. Company management will host a conference call at 4:30 p.m.
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
SAN DIEGO, Feb. 06, 2025 ( GLOBE NEWSWIRE ) -- Crinetics Pharmaceuticals, Inc. ( Nasdaq: CRNX ) today announced that it will report fourth quarter and full year 2024 financial results on Thursday, February 27, 2025 after the market closes. Company management will host a conference call at 4:30 ...
This Netflix Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Hormel Foods ( NYSE:HRL ) , Crinetics Pharmaceuticals ( NASDAQ:CRNX )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Canaccord Genuity analyst Maria Ripps upgraded the rating for Netflix, Inc.
Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN DIEGO, Jan. 10, 2025 ( GLOBE NEWSWIRE ) -- Crinetics Pharmaceuticals, Inc. ( Nasdaq: CRNX ) today announced that on January 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 96,100 shares of its common stock ...
Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential - Neurocrine Biosciences ( NASDAQ:NBIX )
On Friday, the FDA approved Neurocrine Biosciences, Inc.NBIX Crenessity ( crinecerfont ) capsules and oral solution as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal ...
Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN DIEGO, Dec. 10, 2024 ( GLOBE NEWSWIRE ) -- Crinetics Pharmaceuticals, Inc. ( Nasdaq: CRNX ) today announced that on December 10, 2024, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 146,400 shares of its common stock ...
Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences - Crinetics Pharmaceuticals ( NASDAQ:CRNX )
SAN DIEGO, Nov. 15, 2024 ( GLOBE NEWSWIRE ) -- Crinetics Pharmaceuticals, Inc. CRNX, a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today announced that company ...
UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society ( NANETS ) Annual Meeting - Crinetics Pharmaceuticals ( NASDAQ:CRNX )
Novel Nonpeptide Drug Conjugate Platform to be Debuted, Featuring Preclinical Profile of Lead Candidate CRN09682 Targeting SST2-Expressing Tumors, which is on Track for IND Submission Early 2025 Data From Phase 2 Trial of Paltusotine in Carcinoid Syndrome to be Highlighted in Crinetics Symposium ...
Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society ( NANETS ) Annual Meeting - Crinetics Pharmaceuticals ( NASDAQ:CRNX )
Novel Nonpeptide Drug Conjugate Platform to be Debuted, Featuring Preclinical Profile of Lead Candidate CRN09682 Targeting SST2-Expressing Tumors, which is on Track for IND Submission Early 2025 Data From Phase 2 Trial of Paltusotine in Carcinoid Syndrome to be Highlighted in Crinetics Symposium ...
Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Crinetics Pharmaceuticals ( NASDAQ:CRNX )
SAN DIEGO, Nov. 11, 2024 ( GLOBE NEWSWIRE ) -- Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Crinetics Pharmaceuticals ( NASDAQ:CRNX )
SAN DIEGO, Nov. 11, 2024 ( GLOBE NEWSWIRE ) -- Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Crinetics Pharmaceuticals ( NASDAQ:CRNX )
SAN DIEGO, Nov. 11, 2024 ( GLOBE NEWSWIRE ) -- Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Crinetics Pharmaceuticals ( NASDAQ:CRNX )
SAN DIEGO, Nov. 11, 2024 ( GLOBE NEWSWIRE ) -- Crinetics Pharmaceuticals, Inc.
Esperion Therapeutics ( ESPR ) Reports Q3 Loss, Lags Revenue Estimates
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -7.14% and 6.86%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Sage Therapeutics, Inc. ( SAGE ) Reports Q3 Loss, Tops Revenue Estimates
Sage Therapeutics (SAGE) delivered earnings and revenue surprises of -0.66% and 7.55%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Crinetics Pharmaceuticals ( NASDAQ:CRNX )
SAN DIEGO, Oct. 10, 2024 ( GLOBE NEWSWIRE ) -- Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN DIEGO, Oct. 10, 2024 ( GLOBE NEWSWIRE ) -- Crinetics Pharmaceuticals, Inc. ( Nasdaq: CRNX ) today announced that on October 10, 2024, the Compensation Committee of Crinetics' Board of Directors granted non-qualified stock option awards to purchase an aggregate of 258,800 shares of its common ...
Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock - Crinetics Pharmaceuticals ( NASDAQ:CRNX )
SAN DIEGO, Oct. 08, 2024 ( GLOBE NEWSWIRE ) -- Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
SAN DIEGO, Oct. 08, 2024 ( GLOBE NEWSWIRE ) -- Crinetics Pharmaceuticals, Inc. ( Nasdaq: CRNX ) , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, announced today the ...
Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly
SAN DIEGO, Sept. 26, 2024 ( GLOBE NEWSWIRE ) -- Crinetics Pharmaceuticals, Inc. ( Nasdaq: CRNX ) today announced the submission of a New Drug Application ( NDA ) to the U.S. Food and Drug Administration ( FDA ) for paltusotine, the first once-daily, oral, selectively-targeted somatostatin ...
Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN DIEGO, Sept. 10, 2024 ( GLOBE NEWSWIRE ) -- Crinetics Pharmaceuticals, Inc. ( Nasdaq: CRNX ) today announced that on September 10, 2024, the Compensation Committee of Crinetics' Board of Directors granted non-qualified stock option awards to purchase an aggregate of 120,200 shares of its ...
Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Crinetics Pharmaceuticals ( NASDAQ:CRNX )
SAN DIEGO, Aug. 12, 2024 ( GLOBE NEWSWIRE ) -- Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc. ( CRNX ) Reports Q2 Loss, Misses Revenue Estimates
Crinetics Pharmaceuticals (CRNX) delivered earnings and revenue surprises of -9.30% and 70.79%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges - Crinetics Pharmaceuticals ( NASDAQ:CRNX )
SAN DIEGO, Aug. 08, 2024 ( GLOBE NEWSWIRE ) -- Crinetics Pharmaceuticals, Inc.
Aquestive Therapeutics ( AQST ) Reports Q2 Loss, Tops Revenue Estimates
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 72.73% and 59.31%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Zevra Therapeutics ( ZVRA ) Q2 Earnings Expected to Decline
Zevra Therapeutics (ZVRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Crinetics Pharmaceuticals, Inc. ( CRNX ) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Crinetics Pharmaceuticals (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
